Abstract: A method for ascertaining a type of collision of a vehicle includes: receiving acceleration information items, via a reception interface, representing the accelerations of the vehicle in a vehicle longitudinal direction and a vehicle transverse direction; determining a first resultant acceleration information item from a first and a second acceleration information item; determining a second resultant acceleration information item from a third and a fourth acceleration information item; combining the first and second resultant acceleration information items to obtain at least one evaluation information item; and determining the collision type based on the at least one evaluation information item.

Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.

Abstract: A method for ascertaining a type of collision of a vehicle includes: receiving acceleration information items, via a reception interface, representing the accelerations of the vehicle in a vehicle longitudinal direction and a vehicle transverse direction; determining a first resultant acceleration information item from a first and a second acceleration information item; determining a second resultant acceleration information item from a third and a fourth acceleration information item; combining the first and second resultant acceleration information items to obtain at least one evaluation information item; and determining the collision type based on the at least one evaluation information item.

Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.

Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.

Abstract: A method of managing an insurance scheme includes defining a plurality of diseases which are covered by the insurance scheme so that if an insured life contracts one of these diseases they will be paid an amount of funds from the insurer or the insurer will pay or partially pay for treatment of the disease. A request is received from an insured life who has contracted one of the defined diseases. The insured life is provided with a choice of receiving treatment in the country in which they reside or receiving treatment in another country. A selected country is received from the insured life and an amount of funds is paid from the insurer to the insured life wherein the amount of funds is at least partially determined by the selected country.

Abstract: The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (?) cell population, or decreasing gastric or intestinal motility.

Abstract: The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.

Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.

Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.

Abstract: A cooking utensil combining the capabilities of both a whisk and a spatula is arranged with a plurality of resilient wire loops protruding outwardly from a handle forming a cage wherein at least one of the wire loops is provided for with a heat resistant flexible wiper arranged for making contact with and wiping the internal surfaces of a mixing container.

Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction

Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction.

Abstract: The present invention provides a solid phase peptide synthetic method for the preparation of C-terminal alchohols, wherein the improvement consists of using trichloroacetimidate as the linker.

Abstract: The survival and proliferation of Schwann cells can be promoted by culturing such cells in the presence of peptides derived from the EGF-like domain of proteins from the NDF/heregulin family. Colon epithelial cells can be stimulated to multiply and differentiate by culturing such cells in the presence of the same peptides.

Abstract: Schwann cells can be treated in vivo to survive longer and to proliferate by contacting them with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.

Abstract: Colon epithelial cells are stimulated to multiply, grow and mature by contacting them in vivo with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.

Abstract: Novel peptides are described which are biologically active derivatives of the EGF-like domain of NDF/heregulins and which stimulate the proliferation and differentiation of colon epithelial cells and support the survival and growth of Schwann cells.

Abstract: A machine for making mop heads includes a pair of parallel forward moving conveyor chains and a yarn winder upstream of the conveyor chains. A continuous supply of yarn is wound by the winder around the outside of the conveyor chains as the chains are moving forward. Downstream of the winder, two rolls of fabric apply a narrow strip of fabric to the yarn at opposite ends inside the conveyor chains. A pair of sewing machines stitch the fabric to the yarn to form opposite end loops around the conveyor chains. Periodically, the winder is stopped or slowed while the conveyor chains continue to move forward forming a long angled loop in the yarn dividing groups of yarn loops. A centrally located taping device sequentially encircles each group of yarn loops at a point equidistant between the conveyor chains. Downstream of the conveyor chains, a pair of rotating arms collect individual taped and stitched groups of yarn loops and a cutter cuts the fabric strips and yarn between each bunched group.

Abstract: A circuit for combining electronic signal power from multiple input ports to a single set of output terminals or for dividing a single signal at a set of input terminals and providing it to multiple output ports. The circuit has a three-winding transformer and a balance resistor or resistors corresponding to each of the multiple ports. Each port is connected to a first winding of its corresponding transformer. The second windings of the transformers are connected together and to the single set of terminals. Third windings of the transformers are connected together through their corresponding balance resistors.